DeepMed Research

Boryung Pharmaceutical Co., Ltd.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions

Phase 1

Completed

Conditions: Essential Hypertension

Interventions: Drug: BR1015
Drug: BR1015-1
Drug: BR1015-2

First Posted Date: 2024-12-20

Last Posted Date: 2025-04-09

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 58

Registration Number: NCT06744127

Locations: 🇰🇷
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Gwanakgu, Korea, Republic of

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 in Healthy Volunteers Fed Conditions

Phase 1

Completed

Conditions: Essential Hypertension

Interventions: Drug: BR1015
Drug: BR1015-1
Drug: BR1015-2

First Posted Date: 2024-12-20

Last Posted Date: 2025-04-09

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 48

Registration Number: NCT06744062

Locations: 🇰🇷
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Gwanakgu, Korea, Republic of

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions

Phase 1

Completed

Conditions: Essential Hypertension

Interventions: Drug: BR1015
Drug: BR1015-2
Drug: BR1015-3

First Posted Date: 2024-12-20

Last Posted Date: 2025-04-09

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 49

Registration Number: NCT06744439

Locations: 🇰🇷
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Gwanakgu, Korea, Republic of

A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy

Recruiting

Conditions: Type 2 Diabetes

First Posted Date: 2024-10-18

Last Posted Date: 2024-10-18

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 10000

Registration Number: NCT06649162

Locations: 🇰🇷
Andong Hospital, Andong, Gyeongsangbuk-do, Korea, Republic of
🇰🇷
Konkuk University medical center, Seoul, Korea, Republic of

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-3" and "BR1019-2" in Healthy Volunteers

Phase 1

Completed

Conditions: Essential Hypertension
Type 2 Diabetes

Interventions: Drug: BR1019
Drug: BR1019-2
Drug: BR1019-3

First Posted Date: 2024-10-15

Last Posted Date: 2024-12-13

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 52

Registration Number: NCT06636877

Locations: 🇰🇷
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Gwanakgu, Korea, Republic of

A Study to Evaluate Ethanol-induced Symptoms and Safety in Breast Cancer Patients

Recruiting

Conditions: Breast Cancer

First Posted Date: 2024-08-05

Last Posted Date: 2024-08-05

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 1052

Registration Number: NCT06537752

Locations: 🇰🇷
Chung-Ang University Hospital, Seoul, Korea, Republic of
🇰🇷
Uijeongbu Eulji Medical Center, Eulji University, Uijeongbu, Korea, Republic of

A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib

Recruiting

Conditions: Primary Hypercholesterolemia
Mixed Dyslipidemia

First Posted Date: 2024-03-18

Last Posted Date: 2024-04-23

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 8606

Registration Number: NCT06314919

Locations: 🇰🇷
Ewha Womans University Seoul Hospital, Seoul, Korea, Republic of

A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of "BR3005" and Co-administration of "BR3005-1" and "BR3005-2" Under Fed Conditions in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Type2 Diabetes Mellitus

Interventions: Drug: BR3005
Drug: BR3005-1
Drug: BR3005-2

First Posted Date: 2024-03-04

Last Posted Date: 2024-05-24

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 40

Registration Number: NCT06289933

Locations: 🇰🇷
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Gwanakgu, Korea, Republic of

A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of "BR3005" and Co-administration of "BR3005-1" and "BR3005-2" Under Fasting Conditions in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: BR3005
Drug: BR3005-1
Drug: BR3005-2

First Posted Date: 2024-03-04

Last Posted Date: 2024-05-24

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 47

Registration Number: NCT06289920

Locations: 🇰🇷
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Gwanakgu, Korea, Republic of

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2"

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus
Essential Hypertension

Interventions: Drug: BR1019
Drug: BR1019-1
Drug: BR1019-2

First Posted Date: 2024-01-26

Last Posted Date: 2024-04-02

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 52

Registration Number: NCT06226727

Locations: 🇰🇷
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Gwanakgu, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy